Viridian Therapeutics, Inc. (VRDN) Q1 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Later, we will conduct a question and answer session and instructions will be given at that time. As a reminder, this conference call is being recorded. I would now like to hand the call over to Ms. Louisa Stone, Manager of Investor Relations at Viridian. Please go ahead. Thank you and welcome everyone to our first quarter 2024 earnings conference call. The press release reporting our financial results and corporate updates is available on the investors' page of our corporate website at www.viridiantherapeutics.com. Joining me on the call this morning are Steve Mahoney, our President and CEO, Tom Shula, our Chief Medical Officer, and Sean Wu, our Chief Business Officer. Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements regarding our financial outlook, in addition to regulatory product development and commercialization plans and research activities. These statements are subject to risks and uncertainties that could cause actual results to materially differ from those forecasted. A description of these risks can be found in our most recent form 10Q and 10K on file with the SEC. I would now like to turn the call over to Steve Mahoney, our President and CEO. Thanks, Louisa, and welcome everyone to our first quarter earnings call. I'll start by giving a brief overview of Viridian, and then we'll get into more detail about our programs and recent progress. For those of you who are new to the Viridian story, Our strategy is to identify market opportunities where there's a clear unmet need and where there is potential for us to develop differentiated products. We then aim to engineer the best possible therapeutics and then move rapidly to advance our programs to patients. Turning to slide four, slid...